MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ASTRAZENECA PHARMA INDIA LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
ASTRAZENECA PHARMA Quarterly Results (AIDL)
Here are the latest quarterly results of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA financial fact sheet and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ASTRAZENECA PHARMA Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
3
Mar-19 |
3
Jun-19 |
3
Sep-19 |
3
Dec-19 |
3
Mar-20 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 1,614 | 1,614 | 2,152 | 1,903 | 2,046 | 2,085 | 2,239 | 1,949 | |
| Other income | Rs m | 34 | 34 | 35 | 60 | 30 | 32 | 35 | 34 | |
| Turnover | Rs m | 1,649 | 1,647 | 2,187 | 1,963 | 2,076 | 2,116 | 2,273 | 1,983 | |
| Expenses | Rs m | 1,522 | 1,466 | 1,743 | 1,839 | 1,690 | 1,749 | 1,871 | 1,801 | |
| Gross profit | Rs m | 93 | 148 | 409 | 64 | 356 | 336 | 368 | 148 | |
| Depreciation | Rs m | 36 | 37 | 38 | 39 | 46 | 46 | 48 | 45 | |
| Interest | Rs m | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 3 | |
| Profit before tax | Rs m | 92 | 144 | 406 | 85 | 336 | 318 | 352 | 134 | |
| Tax | Rs m | 28 | 53 | 115 | -14 | 121 | 174 | 85 | 38 | |
| Profit after tax | Rs m | 64 | 91 | 291 | 98 | 215 | 144 | 267 | 96 | |
| Gross profit margin | % | 5.7 | 9.1 | 19.0 | 3.3 | 17.4 | 16.1 | 16.4 | 7.6 | |
| Effective tax rate | % | 30.1 | 36.8 | 28.3 | -15.9 | 36.0 | 54.7 | 24.1 | 28.3 | |
| Net profit margin | % | 4.0 | 5.7 | 13.5 | 5.2 | 10.5 | 6.9 | 11.9 | 4.9 | |
| Diluted EPS | Rs | 2.6 | 3.7 | 11.6 | 3.9 | 8.6 | 5.8 | 10.7 | 3.8 | |
| Diluted EPS (TTM) | Rs | 10.7 | 3.4 | 19.1 | 21.8 | 27.8 | 29.9 | 29.0 | 28.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: ASTRAZENECA PHARMA 4QFY20 Result Performance Review
More Pharmaceuticals Company Quarterly Results: AUROBINDO PHARMA ALEMBIC LTD SUVEN LIFESCIENCES DIVIS LABORATORIES ALEMBIC PHARMA
Compare ASTRAZENECA PHARMA With: AUROBINDO PHARMA ALEMBIC LTD SUVEN LIFESCIENCES DIVIS LABORATORIES ALEMBIC PHARMA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Today's Market
Sensex Ends Marginally Lower; Telecom and IT Stocks Witness Selling(Closing)
After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours today and ended marginally lower.
Views on news
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)
May 20, 2020 | Updated on May 20, 2020For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
More Views on NewsMost Popular
Protect Your Wealth from Fund Managers (Fast Profits Daily)
May 14, 2020Do you know how much you are paying in fees to your mutual fund? In this video I'll share with you my views.
Of India's 20 Trillion Stimulus Package and the Swoosh Index for a Swoosh Recovery (Profit Hunter)
May 13, 2020For India's rapid economic recovery, hopping on to the Swoosh index is a must.
How Commodity Prices Tell You When Stocks Will Go Up (Fast Profits Daily)
May 20, 2020Commodity prices often provide clues to big moves in stock markets. In today's video, I'll explain this link.
This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio (Profit Hunter)
May 19, 2020This smallcap company needs no stimulus measures to do well in the long term.
Why Buffet - and you - should study Quantum Liquid Fund (The Honest Truth)
May 14, 2020Ajit Dayal on how Quantum Liquid Fund and Warren Buffett have similar investing styles.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ASTRAZENECA PHARMA SHARE PRICE
May 26, 2020 03:35 PM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - ACTAVIS COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.